Neuroblastoma Treatment Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Neuroblastoma Treatment Market
Neuroblastoma Treatment Market: By Drug (Xalkori, Clafen, Vincasar PFS) By Treatment (Surgery, Chemotherapy, High-dose chemotherapy with stem cell support, Monoclonal antibody treatment, Radiotherapy) & Geography - Forecast(2018 - 2023)
Report Code : HCR 0302
Updated Date: 16 May, 2018  

1. Neuroblastoma Treatment– Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Neuroblastoma Treatment– Market Forces
   4.1. Drivers
      4.1.1. Rising cases of cancer in infants due to life style related health impacts
   4.2. Opportunities
   4.3. Challenges
      4.3.1. Lower awareness in the developing nations
   4.4. Porter’s Five Forces Analysis
      4.4.1. Bargaining Power of Suppliers
      4.4.2. Bargaining Power of Buyers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitutes
      4.4.5. Degree of Competition
5. Neuroblastoma Treatment– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Neuroblastoma Treatment Market, By Drug
   6.1. Xalkori (crizotinib)
   6.2.  Adriamycin PFS (Doxorubicin Hydrochloride)
   6.3. Clafen (Cyclophosphamide)
   6.4. Vincasar PFS (Vincristine Sulfate)
   6.5. Others
7. Neuroblastoma Treatment Market, By Treatment
   7.1. Surgery
   7.2. Chemotherapy
   7.3. High-dose chemotherapy with stem cell support
   7.4. Monoclonal antibody treatment
   7.5. Radiotherapy
   7.6. Others
8. Neuroblastoma Treatment Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Neuroblastoma Treatment– Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Top 10 Companies)
   10.1. Seattle Children’s
   10.2. Cure Search
   10.3. Texas Children’s
   10.4. NANTGE Healthcare
   10.5. Pfizer Inc.
   10.6. GL Pharm Tech Corporation
   10.7. Hôpitaux de ParisOthers
   10.8. Erasmus Medical Center
   10.9. Assistance Publique - Hopitaux de Paris
   10.10. Texas Neurofibromatosis Foundation
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll